To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Feb 25, 2022)
This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19.
Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.)
Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.
What just happenedFeb 28, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseFeb 25, 2022
- Feb 28, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Feb 25, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Financial Services Committee - Feb 25, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Feb 25, 2022IntroReferralIntro-H
Introduced in House
- Feb 25, 2022IntroReferral1000
Introduced in House